top of page

Blogs


ADC Conjugate Ratio to Therapeutic Efficacy in zebrafish
Antibody therapies need evaluation of safety efficacy in physiological models to gain maximum translation benefit. Towards such, ADCs...
Benin Joseph
Jul 221 min read
Â
Â
Â


SYNGAP1 Screening Modalities in Zebrafish
SYNGAP1, a synaptic Ras GTPase activating protein deficiency is associated with severe intellectual disability in humans. Zebrafish...
Dr.Bibhas Kar
Feb 52 min read
Â
Â
Â


An Improved Method for Quantifying Brain Penetrating Drugs in Zebrafish Models
A number of new drugs for neurodegenerative and inflammatory disease focus on target sites primarily within the brain. With human ED50 at...
Dr. Suriya Kayathri
Jul 18, 20242 min read
Â
Â
Â


Do Exceptional Insecticides Exist?
Neuroactive Insecticide Bioactivity Testing
Keerthana Rajendran
Jun 28, 20241 min read
Â
Â
Â


What Precedes ALS?
There is a need to understand fundamental mechanisms that leads to dysregulation trigger; which eventually leads up to neurodegeneration....
Kalaichitra
Jun 17, 20241 min read
Â
Â
Â


Gene Editing without the worry of Liver Edema – Zebrafish Reproducibility Assay
Gene editing primarily focus on threshold of edited protein as an Index of success rate. However in almost all cases, gene editing is met...
Kalaichitra
Nov 29, 20231 min read
Â
Â
Â


mRNA Therapeutics Development solutions with Zebrafish
mRNA therapeutic applications are growing, however at the clinical stage, they are facing a similar failure rate as of small molecules !...
Kalaichitra
Oct 10, 20232 min read
Â
Â
Â


A Clinical Biomarker Assay for ALS Drug Screening in zebrafish model
Key Hallmarks of the Assay: Cortical readings from zebrafish ALS models are generated with the similar sensitivity and readouts as in...
Kalaichitra
Aug 29, 20231 min read
Â
Â
Â


A thorough solution for Rheumatoid Arthritis Discovery with Zebrafish
Current Clinical Challenges: In progressive Rheumatoid Arthritis (RA) candidates are designed to target inflammatory mediators -...
Kalaichitra
Aug 4, 20232 min read
Â
Â
Â
bottom of page